domperidone has been researched along with Regurgitation, Gastric in 3 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Regurgitation, Gastric: GASTROESOPHAGEAL REFLUX wherein the retrograde flow passes through the UPPER ESOPHAGEAL SPHINCTER
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of domperidone in combination with omeprazole in the treatment of laryngopharyngeal reflux (LPR) compare to omeprazole alone." | 9.16 | Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone. ( Hunchaisri, N, 2012) |
| "To evaluate the efficacy of domperidone in combination with omeprazole in the treatment of laryngopharyngeal reflux (LPR) compare to omeprazole alone." | 5.16 | Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone. ( Hunchaisri, N, 2012) |
| "To evaluate the efficacy, safety and tolerability of fixed dose combination of Rabeprazole (enteric-coated, EC) 20 mg + Domperidone (sustained release, SR) 30 mg for treatment of laryngopharyngeal reflux disease (LPRD)." | 3.81 | An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref ( Mukaddam, QI; Naik, M; Semmanaselvan, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Semmanaselvan, K | 1 |
| Mukaddam, QI | 1 |
| Naik, M | 1 |
| Ndraha, S | 1 |
| Hunchaisri, N | 1 |
2 trials available for domperidone and Regurgitation, Gastric
| Article | Year |
|---|---|
Combination of PPI with a prokinetic drug in gastroesophageal reflux disease.
Topics: Administration, Oral; Adult; Antiemetics; Domperidone; Double-Blind Method; Drug Synergism; Drug The | 2011 |
Treatment of laryngopharyngeal reflux: a comparison between domperidone plus omeprazole and omeprazole alone.
Topics: Anti-Ulcer Agents; Chi-Square Distribution; Domperidone; Dopamine Antagonists; Drug Therapy, Combina | 2012 |
1 other study available for domperidone and Regurgitation, Gastric
| Article | Year |
|---|---|
An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Ref
Topics: Adult; Aged; Capsules; Delayed-Action Preparations; Domperidone; Dopamine Antagonists; Female; Human | 2015 |